Returns Chart

Key Stats

Customize

Basic Info

Investment Strategy
The fund’s investment objective is to provide unitholders with exposure to biotechnology and healthcare companies with: (i) the opportunity for capital appreciation; (ii) monthly cash distributions; and (iii) lower volatility of investment portfolio returns when compared to owning the underlying securities of the fund directly. Investments by the fund may be made globally.
General
Security Type Mutual Fund
Oldest Share Symbol --
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index --
Prospectus Objective --
Fund Owner Firm Name Purpose Investments Inc.
Prospectus Benchmark Index
N/A 100.0%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Vlad Tasevski 0.37 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: --
-391.33M Category Low
445.62M Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of June 30, 2022

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of July 05, 2022. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-7.76%
21.36%
9.78%
-7.58%
21.93%
5.56%
28.04%
-9.48%
21.67%
-10.02%
8.89%
6.23%
14.77%
11.47%
18.82%
-7.04%
--
-9.59%
1.16%
9.38%
2.74%
6.66%
6.09%
-11.65%
--
--
--
--
--
--
21.21%
-6.51%
14.12%
-19.14%
6.42%
1.06%
11.87%
11.96%
-0.98%
-7.26%
As of July 05, 2022.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (7-5-22) 0.00%
30-Day SEC Yield --
7-Day SEC Yield (5-26-22) Upgrade
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 20.67
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 31, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 31, 2022

Asset Allocation

As of May 31, 2022.
Type % Net % Long % Short
Cash 4.64% Upgrade Upgrade
Stock 95.36% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Johnson & Johnson 4.33% 178.14 0.00%
Pfizer Inc 4.10% 52.40 1.47%
Regeneron Pharmaceuticals Inc 3.69% 600.33 0.63%
Thermo Fisher Scientific Inc 3.43% 547.52 0.45%
Eli Lilly and Co 3.41% 328.96 0.54%
Abbott Laboratories 3.40% 108.32 -0.90%
Merck & Co Inc 3.11% 94.15 1.63%
UnitedHealth Group Inc 3.00% 511.53 1.24%
Amgen Inc 2.79% 246.57 -0.06%
Zoetis Inc Class A 2.48% 176.70 1.41%

Fees & Availability

Fees
Actual 12B-1 Fee --
Actual Management Fee Upgrade
Administration Fee --
Performance Fee --
Switching Fee Upgrade
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP Yes
Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment Upgrade
Minimum Subsequent Investment Upgrade

Basic Info

Investment Strategy
The fund’s investment objective is to provide unitholders with exposure to biotechnology and healthcare companies with: (i) the opportunity for capital appreciation; (ii) monthly cash distributions; and (iii) lower volatility of investment portfolio returns when compared to owning the underlying securities of the fund directly. Investments by the fund may be made globally.
General
Security Type Mutual Fund
Oldest Share Symbol --
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index --
Prospectus Objective --
Fund Owner Firm Name Purpose Investments Inc.
Prospectus Benchmark Index
N/A 100.0%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Vlad Tasevski 0.37 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (7-5-22) 0.00%
30-Day SEC Yield --
7-Day SEC Yield (5-26-22) Upgrade
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 20.67
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 31, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 31, 2022

Fund Details

Key Dates
Inception Date 1/18/2022
Last Annual Report Date 12/31/2021
Last Prospectus Date --
Share Classes
PFC5201 Fee-based Advice
PFC5202 Institutional
Attributes
Enhanced Index Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

Top Portfolio Holders

0 of 0